Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://www.nature.com/cgi-taf/DynaPage.taf?file=/gt/journal/v10/n3/abs/3301886a.html&filetype=&_UserReference=C0A804ED46501B1BE8A2E1039D1A3E484917

nature.com nature publishing group nature science update naturejobs help
Nature Publishing Group Gene Therapy
SEARCH     advanced search my account e-alerts subscribe register
Journal home
For readers
Content
Online sample issue
E-alerts
Indexed in
For authors
Editor
Instructions for authors
Scope
Customer services
Subscribe
Prices
Order sample copy
Purchase articles, reprints & permissions
Recommend to your
library
Contact us
Advertising
Society publishing
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Clinical Medicine Clinical Medicine
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences NEW!
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials
Medical Research Medical Research
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
 
February 2003, Volume 10, Number 3, Pages 251-260
Table of contents    Previous  Abstract  Next   Full text  PDF
Space
Research Article
Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines
Space
J Bramson1, K Dayball1, C Evelegh1, Y H Wan1, D Page2 and A Smith3
Space
1Department of Pathology and Molecular Medicine, Center for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada

2Elan Pharmaceutical Technologies, Trinity College, Dublin, Ireland

3Altea Genomics, Inc., Atlanta, GA, USA

Correspondence to: Dr J Bramson, Department of Pathology and Molecular Medicine, McMaster University, Room HSC-4H21B, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
Space
Abstract
Space

The skin represents an excellent site for vaccine inoculation due to its natural role as a first line of contact with foreign pathogens and the high local frequency of antigen presenting cells. To facilitate skin-directed immunization, a new technique has been developed (termed microporation) whereby a vaporization process is used to remove tiny areas of the stratum corneum creating microscopic pores that allow access to the underlying viable epidermis. Reporter gene expression was 100-fold increased following application of an adenovirus vector to microporated skin when compared to intact skin. Furthermore, 10-100-fold greater cellular and humoral immune responses were observed following topical administration of an adenovirus vaccine to microporated skin versus intact skin. Hairless mice responded to the microporated adenovirus vaccine equivalently to mice with normal hair follicle distribution demonstrating the activity of the microporated vaccine was not related to follicle count. In a tumor challenge model using a surrogate antigen, microporation increased vaccine efficacy by approximately 100-fold compared to intact skin. Finally, microporation enabled delivery of an adenovirus vaccine carrying a relevant melanoma antigen resulting in the development of auto-immune vitiligo and tumor protection. Thus, the microporation technology has proven to be a reliable and easy method to enable skin-directed vaccination.

Gene Therapy (2003) 10, 251-260. doi:10.1038/sj.gt.3301886

Space
Keywords
Space
skin; topical immunization; genetic vaccine
 
Space
Space
Space
Received 8 May 2002; accepted 29 July 2002
Space
February 2003, Volume 10, Number 3, Pages 251-260
Table of contents    Previous  Abstract  Next   Full text  PDF
Privacy Policy © 2003 Nature Publishing Group

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.